Science news

<<  return


ABSORB-3 at 2 Years: More CV Events With Absorb BVS vs Xience

Patients who received the Absorb (Abbott Vascular) bioresorbable vascular scaffold (BVS) in the ABSORB-3 trial showed a primary outcome, counting only events occurring between the 1-year and 2-year marks, that was noninferior to that of patients who had been stented with the same company"s Xience everolimus-eluting metal stent.

But cumulative events in the study out to 25 months told a different story, one in which major adverse cardiac events were more prevalent with the groundbreaking Absorb stent compared with the popular Xience. By then, the rate of the target-lesion failure (TLF) primary end point—a composite of cardiac death, target-vessel MI, or ischemia-driven target lesion revascularization—came to 10.9% for the 1322 patients in the Absorb BVS group and 7.8% for the 686 who had been randomized to Xience. The end point"s hazard ratio (HR) was 1.42 (95% CI 1.04–1.94) P=0.03).